---
title: "Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy. Clinical evidence covers CAPTIVATE and DNTH103-AU-001. 373 evidence topics quoted from 143 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Claseprubart

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Chronic inflammatory demyelinating polyneuropathy

<a id="topic-1.1.1-1"></a>

##### Summary

In a 2023 US claims analysis, the adjusted prevalence of CIDP was 23.3 per 100,000 persons, corresponding to an estimated 77,058 individuals, and the adjusted incidence was 2.8 per 100,000 persons, or approximately 9,238 patients diagnosed in 2023. Pooled estimates across studies were a prevalence of 2.81 per 100,000 and a crude incidence of 0.33 per 100,000 person-years, and heterogeneity across studies was partly explained by the use of different diagnostic criteria. In one survey, 78% of patients had a progressive or relapsing course and 18% could not walk independently at the last visit; pooled estimates across studies were a remission rate of 40.8% and a case fatality rate of 3.3%.

Health-related quality of life is reduced. In a cross-sectional survey in eight countries including the United States, in which 164 physicians provided data for 1056 participants, the mean EQ-5D-5L score was 0.662, and the authors reported lower HRQoL than in the general population; a review of humanistic burden studies reported that, in one study (n = 76), 17% and 74% of patients reported severe pain and severe fatigue, respectively. In a survey of individuals with self-reported CIDP, 44% of those with likely CIDP stopped working because of their symptoms.

In a US claims case-control analysis, mean total costs over 2 years were $116,330 for 790 cases compared with $15,586 for 790 matched controls, and CIDP therapy accounted for 51.2% of mean total costs among cases. In a second US claims analysis, mean first-year all-cause cost was $105,554 for all patients and $247,456 for chronic immunoglobulin users, who made up 62% of immunoglobulin users.

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/); [Broers et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518865/); [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/); [Al-Zuhairy and Jakobsen (2023)](https://pubmed.ncbi.nlm.nih.gov/36928889/); [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/); [Querol et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8463372/); [Allen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854453/); [Divino et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6198979/); [Guptill et al. (2024)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/136957)

<a id="heading-1.1.2"></a>

#### 1.1.2 Claseprubart Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

No randomized efficacy results for claseprubart in CIDP have been reported. CAPTIVATE is a phase 3 trial with an open-label Part A, in which participants receive claseprubart 300 mg subcutaneously every 2 weeks after an intravenous loading dose, followed by a randomized, placebo-controlled withdrawal Part B with time to relapse on the adjusted INCAT score as the primary endpoint. In the interim responder analysis of Part A, 30 of the first 40 participants (75%) were confirmed responders, defined as a decrease of at least 1 point in the adjusted INCAT score, against a target response rate of 50% or greater. Of the 10 non-responders, 5 had stable CIDP and 5 had a relapse. In confirmed responders, the mean (SD) change from Part A baseline was –1.6 (0.89) on INCAT, 15.9 (12.78) in grip strength, 5.1 (3.93) on the MRC-SS, and 8.9 (12.08) on I-RODS.

In the same interim analysis set (N=40), 24 participants (60%) had an adverse event and 1 (3%) had a serious adverse event, a grade 3 ureterolithiasis assessed as not treatment-related. No treatment-related infections, serious infections, or adverse events leading to discontinuation were reported. In the phase 1 study in healthy volunteers, no serious adverse events were reported, five participants had mild or moderate treatment-related adverse events, and two participants in the 50 mg/kg intravenous cohort became antinuclear antibody positive at Day 57 without evidence of SLE.

These results are from an interim analysis of the open-label Part A; the company describes the summaries as preliminary and states that the study remains ongoing and the data are not final. Top-line results from all participants completing Part A are expected by the end of 2027 and from Part B by the end of 2028.

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9); [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3); [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm); [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm); [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Claseprubart

<a id="topic-1.1.3-1"></a>

##### Summary

No price for claseprubart has been announced and no budget impact model of claseprubart has been published. A company presentation on the US CIDP market assumes an immunoglobulin price per patient of approximately $150,000 per year and an average biologic net price per patient of approximately $700,000 per year.

Published economic evidence concerns efgartigimod alfa injection and immunoglobulin. The Canadian CDA-AMC review estimated an incremental cost-effectiveness ratio for efgartigimod alfa injection of $1,872,111 per QALY gained compared with immunoglobulin, an annual cost of $1,030,527 per patient, and an incremental budget impact of approximately $691 million over the first 3 years. The second NICE draft guidance, open for consultation from 03 November 2026 to 23 November 2026, states that efgartigimod should not be used to treat progressive or relapsing active CIDP in adults after corticosteroids or immunoglobulins. In a US budget impact model for a hypothetical 25-million-member health plan with 708 immunoglobulin-treated patients, a 10% uptake of efgartigimod alfa in year 1 yielded a projected budget impact of $45,996,708, a 35.5% increase. A cost per responder analysis reported 12-month costs per responder of $256,792 for Panzyga 1 g/kg and $1,455,382 for Vyvgart Hytrulo.

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1); [CDA-AMC efgartigimod alfa reimbursement recommendation (2026)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/SR0894/2990?inline=1); [NICE ID6409 draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11508/documents/draft-guidance-2); [NICE ID6409 project information (2026)](https://www.nice.org.uk/guidance/indevelopment/gid-ta11508); [Mallick et al. (2025)](https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-002929.html); [Muley et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42764727/)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

CIDP affected an estimated 77,058 individuals in the United States in 2023, 78% of patients in one survey had a progressive or relapsing course, and in US claims mean total costs were 7.5 times those of matched controls ($116,330 compared with $15,586), with CIDP therapy accounting for 51.2% of mean total costs among cases. Around a third of patients do not respond to current treatments and approximately two-thirds need long-term intravenous immunoglobulin. For Vyvgart Hytrulo (efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase), approved for CIDP in June 2024, CDA-AMC estimated $1,872,111 per QALY gained for efgartigimod alfa injection compared with immunoglobulin, and NICE draft guidance states that efgartigimod should not be used.

Claseprubart is an investigational monoclonal antibody that selectively inhibits the active form of C1s. The evidence in CIDP consists of an open-label interim analysis of 40 participants in Part A of the phase 3 CAPTIVATE trial, in which 75% were confirmed responders and no treatment-related serious adverse events or serious infections were reported, together with phase 1 data in healthy volunteers. No randomized results, peer-reviewed publication, price, or budget impact model exist. The company believes that CAPTIVATE, as a single pivotal trial, will support a Biologics License Application, with Part B top-line results expected by the end of 2028. The company states that the safety and efficacy of claseprubart have not been evaluated in head-to-head comparative clinical studies.

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/); [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/); [Divino et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6198979/); [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf); [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1); [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/); [van Schaik et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29122523/); [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm); [CDA-AMC efgartigimod alfa reimbursement recommendation (2026)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/SR0894/2990?inline=1); [NICE ID6409 draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11508/documents/draft-guidance-2); [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9); [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm); [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
